Invest Daily Pro
  • Economy
  • Investing
No Result
View All Result
  • Economy
  • Investing
No Result
View All Result
Invest Daily Pro
No Result
View All Result
Home Economy

Upperton Wins Pharma Project of the Year at 2024 Pharma Industry Awards UK

by
September 25, 2024
in Economy, Investing
0
Upperton Wins Pharma Project of the Year at 2024 Pharma Industry Awards UK
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Last Updated on:

Upperton Pharma Solutions has been awarded the Pharma Project of the Year at the Pharma Industry Awards UK 2024, held at Birmingham’s International Convention Centre (ICC) on Wednesday, 18th September. The event recognised excellence across the pharmaceutical and biotech sectors, celebrating achievements in a range of categories.

Upperton triumphed over competitors Sanofi and Bouygues Energies & Services for its exceptional work on the 50,000-square-foot Trent Gateway facility, which was noted for its outstanding project management, strategic collaboration with UK-based suppliers, and swift delivery, taking just 10 months to complete.

The Trent Gateway facility represents a major expansion for Upperton, incorporating 10 GMP manufacturing suites alongside quality control laboratories, formulation development labs, analytical labs, and pilot plant spaces. This state-of-the-art facility enhances Upperton’s ability to meet rising client demand and further advance its services in pharmaceutical development.

Ian Lafferty, Chief Technical Officer and Project Lead for Trent Gateway, praised the team’s dedication: “This award is the culmination of 18 months of hard work by our team. To build a facility of this quality within 10 months is an outstanding achievement. To then validate, commission and receive MHRA Approval provided us with a platform to develop and manufacture on a new scale for our customers.”

Nikki Whitfield, Upperton’s Chief Executive Officer, reflected on the achievement: “To be recognised for our Trent Gateway facility is an outstanding achievement. The state-of-the-art facility satisfies our increasing customer demand and extends our service offering further along the drug development pathway. The facility meets our clients’ requirements from a complexity, scale, and potency perspective, whilst adhering to all the necessary regulatory requirements. The dedication and attention to detail by our team have allowed us to elevate our services while working with the best talent in the Midlands and the wider sector. This facility is a testament to our commitment to growth and innovation.”

The Pharma Project of the Year award highlights Upperton’s innovative approach to working with UK supply chains and delivering cutting-edge pharmaceutical development and manufacturing solutions.

Trent Gateway is designed to support the development and production of various dosage forms, including oral solids, liquids, semi-solids, nasal, and inhaled products. The facility facilitates early-stage formulation and offers clinical trial supplies from Phase 1 to Phase 3. Its GMP infrastructure, state-of-the-art equipment, and containment capabilities allow it to handle batch sizes of up to 250kg, supporting larger-scale manufacturing operations.

ShareTweetPin

Related Posts

Blue Lagoon’s Dome Mountain Joins BC’s Select List of Permitted Projects
Investing

Blue Lagoon’s Dome Mountain Joins BC’s Select List of Permitted Projects

June 2, 2025
Harmony Gold to Acquire MAC Copper in US$1.03 Billion Deal
Investing

Harmony Gold to Acquire MAC Copper in US$1.03 Billion Deal

June 2, 2025
Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout
Investing

Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout

June 1, 2025
Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain
Investing

Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

May 31, 2025
NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit
Investing

NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

May 31, 2025
CDX May Investor Presentation
Investing

CDX May Investor Presentation

May 30, 2025
Next Post
Royal jeweller cuts prices by 20% to counter impact of tourist tax

Royal jeweller cuts prices by 20% to counter impact of tourist tax

Recommended

‘X’ marks new era for Volvo

‘X’ marks new era for Volvo

December 8, 2024
Glass Pharms Welcomes Adam George as New Chairman

Glass Pharms Welcomes Adam George as New Chairman

January 8, 2025
Initial work starts on preparing three ports to serve offshore wind farms

Initial work starts on preparing three ports to serve offshore wind farms

September 22, 2024
SEC clears P2.87-B Topline IPO; Nov. 22 listing eyed

SEC clears P2.87-B Topline IPO; Nov. 22 listing eyed

October 9, 2024
BSP rate cuts to boost consumption, spur business expansion — Metrobank

BSP rate cuts to boost consumption, spur business expansion — Metrobank

October 23, 2024
German chamber finds energy costs, logistics topping businesses’ concerns

German chamber finds energy costs, logistics topping businesses’ concerns

January 7, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 InvestDailyPro. All Rights Reserved.

    Disclaimer: InvestDailyPro.com, its managers, its employees, and assigns (collectively InvestDailyPro ) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
    The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    No Result
    View All Result
    • About us
    • Contact us
    • Home
    • Privacy Policy
    • Suspicious engagement
    • Terms & Conditions
    • Terms & Conditions
    • Thank you

    Copyright © 2024 investdailypro.com | All Rights Reserved